SCHEMBL128641

SCHEMBL128641

CCCCOc1cc[c]cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.42
CYP3A4 P08684 3/20 0.42
LTA4H P09960 4/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36
GABRE P78334 1/20 0.36
GABRA6 Q16445 1/20 0.36
GABRG1 Q8N1C3 1/20 0.36
GABRG3 Q99928 1/20 0.36
GABRQ Q9UN88 1/20 0.36
CYP1A2 P05177 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2220469 0.94 CYP3A4 (0.39) CYP2D6CYP3A4LTA4HNR5A1RAB9A
SCHEMBL10388381 0.93 CYP3A4 (0.41) CYP2D6CYP3A4LTA4HNR5A1RAB9A
SCHEMBL130932 0.90 GABRP (0.34) CYP2D6CYP3A4LTA4HGABRPGABRD
SCHEMBL131609 0.82
SCHEMBL13518659 0.81 NCF1 (0.36)
SCHEMBL2067241 0.81 TSHR (0.35) TSHR
SCHEMBL2067093 0.81 CHEK1 (0.32)
SCHEMBL933103 0.80 KDM4E (0.43) CYP2D6CYP3A4CYP1A2CYP2C9CYP2C19
SCHEMBL6706172 0.79 SIGMAR1 (0.41) CYP2D6LTA4HCYP1A2CYP2C9CYP2C19
SCHEMBL6352955 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP claimed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP claimed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP claimed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US claimed
CN-101460497-A Pyrrolopyridine and thiazolopyridine compounds as HIF modulators FIBROGEN INC (US) 2009-06-17 CN claimed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP claimed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US claimed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO claimed
EP-0674637-B1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LTD (GB) 1998-09-23 EP claimed
US-5731323-A Quinuclidine derivatives as squalene synthase inhibitors ZENECA LIMITED (GB) 1998-03-24 US claimed
EP-0674637-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1995-10-04 EP claimed
CN-1094404-A Heterogeneous ring compound ZENECA LTD (GB) 1994-11-02 CN claimed
WO-1994014805-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1994-07-07 WO claimed
EP-4023640-A1 PHENYLIMIDAZOLE COMPOUND Otsuka Pharmaceutical Factory, Inc. (JP) 2022-07-06 EP disclosed
CN-113200962-A Phenylimidazole compounds 株式会社大塚制药工场 2021-08-03 CN disclosed
CN-108430977-B Phenylimidazole compounds 株式会社大塚制药工场 2021-06-08 CN disclosed
EP-0674637-B1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LTD (GB) 1998-09-23 EP disclosed
US-5731323-A Quinuclidine derivatives as squalene synthase inhibitors ZENECA LIMITED (GB) 1998-03-24 US disclosed
EP-0674637-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1995-10-04 EP disclosed
WO-1994014805-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 CYP2D6 2894/4885CYP3A4 2477/4885LTA4H 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.